Pierre E. G. Etienne, M.D.
Chief Development Officer

Pierre E. G. Etienne, M.D. has served as Chief Development Officer of Targanta since September 2006. He joined Targanta (then PhageTech) in June 2003 as Chief Executive Officer of the Company's Montreal, Canada-based subsidiary. From 1996 to 2003, Dr. Etienne was a Vice President, World Wide Clinical Study Management at Pfizer Inc., accountable for the clinical execution of all Phase 2 and Phase 3 trials. From 1989 to 1992, he led the experimental medicine group at Pfizer U.S. Laboratories in Groton, CT. From 1992 to 1996, Dr. Etienne led Pfizer's early clinical research group.

Dr. Etienne holds an M.D. degree from Université de Liège, Belgium and trained in neurochemistry and psychiatry at McGill University in Montreal. Before joining industry, he was chief investigator on an MRC (Canada) program grant on the cholinergic hypothesis of Alzheimer's disease. Over his professional career, Dr. Etienne has developed significant experience in academic-industrial relations, the transition of compounds from the pre-clinical to the clinical stage, their early characterization, and their valuation. He also has acquired a significant world expertise in the execution of trials for registration in the U.S., Europe, and Japan.

Dr. Etienne is a director of ESVEE Pharmaceuticals, Private Limited in Pune, India and a principal of Decision Options, LLC in Groton, CT. Dr. Etienne sits on the advisory board of Del-Mar Therapeutics, in La Jolla, CA and on the development council of Neurogen, Inc. in Branford, CT.